Oral chemotherapeutic agents have been available for many years, and were traditionally cytotoxic drugs, such as cyclophosphamide, methotrexate, and mercaptopurine. In recent years, oral anticancer medications are being used more often in many types of cancer.
Retrospective Analysis of Probiotic Effectiveness in Patients with Acute Myeloid Leukemia or Patients Undergoing Transplant Who Are Receiving Chemotherapy
It is well-known that patients with acute myeloid leukemia (AML) who receive induction and reinduction chemotherapy and any patients undergoing hematopoietic stem-cell transplant (HSCT) are at high risk for infections and prolonged hospital stays. Intensive chemotherapy regimens used in these settings cause patients to be neutropenic for prolonged durations.
Pain is one of the most feared symptoms of cancer, with uncontrolled pain being the most frequently reported symptom in hospitalized patients with cancer. As cancer stage progresses, the pain intensity and incidence increase, with cancer pain reported in 62% to 86% of patients with advanced disease.
Comparing Oral Chemotherapy Safe Prescribing Practices in an Academic Health System: A Retrospective Analysis
Anastasia Finn, PharmD, MBA, BCOP, Jesse Young, PharmD, Kathy Edwards, PharmD, BCPS, BCOP, Andy Perez, PharmD, BCOP, Shawn MacVane, PharmD, BCPS
Treatment of Clostridium difficile infection presents a unique challenge in patients with cancer. C difficile infections are often related to the use of antibiotics and to hospitalizations, and patients undergoing chemotherapy treatment may be at a particularly high risk for infection.
Efficacy and Cost Analysis of a Plerixafor Protocol for Peripheral Blood Stem-Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma
The Effect of Written Pharmacist-Provided Patient Education for 3 Frequently Prescribed Oral Anticancer Agents on the Incidence of Patient-Initiated Triage Calls
Nicolas De Padova, PharmD, Robert Grabowski, PharmD, Joseph Ineck, PharmD, CPE, Robert Mancini, PharmD, BCOP
Determination of Extended Sterility for Single-Use Vials Using the PhaSeal Closed-System Transfer Device
Kristin V. Ho, PharmD, BCOP, Michael S. Edwards, PharmD, MBA, BCOP, Dominic A. Solimando, Jr, MA, BCOP, Anthony D. Johnson, CPhT
Neutropenia Recovery Linked to Filgrastim Initiation Timing After Autologous Hematopoietic Stem-Cell Transplantation
Marissa Janusek, PharmD, Lisa DiGrazia, PharmD, BCPS, BCOP, Kathryn Schultz, PharmD, BCPS, BCOP, Laura Geswein, PharmD, BCPS, Christopher W. Crank, PharmD, BCPS, MS, AQ-ID, Henry C. Fung, MD, FRCPE
High doses of chemotherapy in patients who undergo autologous hematopoietic stem-cell transplantation (HSCT) can result in delayed or incomplete engraftment. Granulocyte colony-stimulating factors are used to decrease the time to engraftment; however, the optimal timing of filgrastim initiation following autologous HSCT is unknown.
Page 1 of 4
Results 1 - 10 of 36
Results 1 - 10 of 36